What happened, in summary

Michelle had been living with ALK-positive lung cancer since 2018 when she developed persistent headaches, vomiting, ear popping, and a whooshing sound in her head. Remembering another patient who had developed leptomeningeal disease, she pressed for an urgent brain MRI despite initial reluctance from the clinic. The scan showed swelling, and further testing over the next several days confirmed cancer in the cerebrospinal fluid and leptomeninges surrounding the brain and spinal cord.

The first prognosis she received was extremely poor, but two visitors to her hospital room directed her to a neuro-oncologist with expertise in leptomeningeal disease. Michelle was considered a candidate for combined targeted therapy and proton craniospinal irradiation. The ALK-positive mutation, early recognition of the complication, and her overall condition all supported the treatment choice. After treatment, no detectable leptomeningeal disease remained.

Recovery still required creating an individualized rehabilitation plan because there was no standard pathway for someone in her situation. The expected mix of disease and treatment effects passed with minimal pain, and she continued working toward greater independence, including the possibility of driving again. Michelle credited self-advocacy and a broad specialist team—including thoracic, radiation, neuro-oncology, psychological, dental, ocular, palliative, and primary-care support—with helping her reach recovery.